Sensei Biotherapeutics (NASDAQ:SNSE) Announces Earnings Results

Sensei Biotherapeutics (NASDAQ:SNSE) announced its earnings results on Monday. The company reported ($3.74) earnings per share for the quarter, beating the consensus estimate of ($4.81) by $1.07, FiscalAI reports.

Sensei Biotherapeutics Trading Down 9.2%

Shares of SNSE opened at $25.13 on Tuesday. The firm has a fifty day moving average price of $21.50 and a 200-day moving average price of $13.88. The firm has a market capitalization of $31.66 million, a P/E ratio of -1.31 and a beta of -0.14. Sensei Biotherapeutics has a 12-month low of $5.00 and a 12-month high of $36.76.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on SNSE. Wall Street Zen raised shares of Sensei Biotherapeutics to a “hold” rating in a research report on Saturday, December 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Sensei Biotherapeutics in a research report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $30.00.

Institutional Investors Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC grew its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,516 shares of the company’s stock after acquiring an additional 1,100 shares during the period. Renaissance Technologies LLC owned 0.91% of Sensei Biotherapeutics worth $123,000 at the end of the most recent reporting period. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.